切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2025, Vol. 19 ›› Issue (06) : 800 -808. doi: 10.3877/cma.j.issn.1674-3253.2025.06.019

综述

前列腺癌早期筛查的常见方法及最新研究进展
胡博文1, 胡亚兰2, 梁辉1,†()   
  1. 1518000　广东，深圳市龙华区人民医院泌尿外科
    2523808　东莞，广东医科大学医学技术学院
  • 收稿日期:2025-03-21 出版日期:2025-12-01
  • 通信作者: 梁辉
  • 基金资助:
    深圳市龙华区医学会医学科研专项课题(2023LHMA26)

Common methods and research advances in early screening for prostate cancer

Bowen Hu1, Yalan Hu2, Hui Liang1,†()   

  1. 1Department of Urology, The People's Hospital of Longhua, Shenzhen, Guangdong 518109, China
    2School of Medical Technology, Guangdong Medical University, Dongguan 523808, China
  • Received:2025-03-21 Published:2025-12-01
  • Corresponding author: Hui Liang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

胡博文, 胡亚兰, 梁辉. 前列腺癌早期筛查的常见方法及最新研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 800-808.

Bowen Hu, Yalan Hu, Hui Liang. Common methods and research advances in early screening for prostate cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 800-808.

前列腺癌（PCa）是全球男性中发病率和死亡率均较高的恶性肿瘤，其早期症状隐匿，使得早期筛查与诊断至关重要。本综述系统阐述了PCa早期筛查的常见方法及最新研究进展。传统方法如直肠指诊（DRE）和前列腺特异性抗原（PSA）检测虽临床应用广泛，但分别存在操作者依赖性高和特异性不足的局限性，可能导致漏诊或过度诊断。近年来，影像学技术取得了显著进步，多参数磁共振成像（mpMRI）已成为评估疑似病灶和引导靶向活检的核心手段；经直肠超声（TRUS）的衍生技术（如超微血流成像、超声造影、弹性成像）通过多模态融合显著提升了诊断效能；正电子发射断层扫描/X线计算机体层成像（PET/CT），尤其是前列腺特异性膜抗原（PSMA）靶向PET/CT，在精准分期和转移灶检测中展现出巨大潜力。同时，新兴生物标志物如前列腺健康指数（PHI）、4Kscore、尿液中的非编码RNA（如PCA3）以及循环肿瘤DNA（ctDNA）等液体活检技术，为无创、精准的风险分层和个体化诊疗提供了新方向。此外，基于分子特征和影像组学的风险预测模型正推动PCa诊疗向个性化医疗迈进。

关键词: 前列腺癌, 早期诊断, 筛查, 生物标志物, 液体活检

Prostate cancer (PCa) is a malignant tumor with high incidence and mortality rates worldwide. Its insidious early symptoms make early screening and diagnosis crucial. This review systematically elaborates on the common methods and latest research advances in early screening for PCa. Traditional methods such as digital rectal examination (DRE) and prostate-specific antigen (PSA) testing, while widely used clinically, have limitations including high operator dependence and insufficient specificity, potentially leading to missed diagnoses or overdiagnosis. In recent years, significant progress has been made in imaging techniques. Multiparametric magnetic resonance imaging (mpMRI) has become a cornerstone for evaluating suspicious lesions and guiding targeted biopsies. Derived technologies of transrectal ultrasound (TRUS), such as superb microvascular imaging (SMI), contrast-enhanced ultrasound (CEUS), and elastography, have significantly improved diagnostic efficacy through multimodal fusion. Positron emission tomography/computed tomography (PET/CT), particularly prostate-specific membrane antigen (PSMA)-targeted PET/CT, shows great potential in precise staging and detection of metastatic lesions. Meanwhile, emerging biomarkers such as the prostate health index (PHI), 4Kscore, urinary non-coding RNAs (e.g., PCA3), and circulating tumor DNA (ctDNA) from liquid biopsies provide new avenues for non-invasive and precise risk stratification and personalized diagnosis and treatment. Furthermore, risk prediction models based on molecular characteristics and radiomics are advancing PCa management towards personalized medicine.

Key words: Prostate cancer, Diagnosis, Screening, Biomarkers, Liquid biopsy
[1]
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023 ,73(3): 33-254.
[2]
葛圣阳, 李伟, 于文强. 2023年度肿瘤甲基化标志物研究进展年终盘点[J]. 中国癌症防治杂志, 2024, 16(1): 10-16. DOI: 10.3969/j.issn.1674-5671.2024.01.02.
[3]
潘剑, 朱耀, 戴波, 等. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217. DOI: 10.19401/j.cnki.1007-3639.2023.03.003.
[4]
Ying Y, He W, Xiong Q, et al. Value of digital rectal examination in patients with suspected prostate cancer: a prospective cohort analysis study[J]. Transl Androl Urol, 2023, 12(11): 1666-1672. DOI: 10.21037/tau-23-371.
[5]
Matsukawa A, Yanagisawa T, Bekku K, et al. Comparing the performance of digital rectal examination and PSA as a screening test for prostate cancer: a systematic review and meta-analysis[J]. Eur Urol, 2024, 85: S413-S414. DOI: 10.1016/s0302-2838(24)00375-0.
[6]
da Silva Junior MM, Capibaribe DM, Avilez ND, et al. Digital rectal examination impact on PSA derivatives and prostate biopsy triggers: a contemporary study[J]. Int Urol Nephrol, 2022, 54(9): 2117-2123. DOI: 10.1007/s11255-022-03283-5.
[7]
殷桂草, 田浩宇, 田锋, 等. 以PSA筛查为基础前列腺癌早期诊断与治疗的研究[J]. 蚌埠医学院学报, 2023, 48(4): 441-444. DOI: 10.13898/j.cnki.issn.1000-2200.2023.04.005.
[8]
王森, 徐瑞芳, 郭晓虎, 等. 联合使用PSA等三项指标在前列腺癌早期筛查中的应用[J]. 上海预防医学, 2020, 32(6): 502-505. DOI: 10.19428/j.cnki.sjpm.2020.19170.
[9]
Remmers S, Bangma CH, Godtman RA, et al. Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European randomized study of screening for prostate cancer[J]. Eur Urol, 2023, 84(5): 503-509. DOI: 10.1016/j.eururo.2023.03.031.
[10]
Kohestani K, Månsson M, Arnsrud Godtman R, et al. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate[J]. Scand J Urol, 2021, 55(2): 116-124. DOI: 10.1080/21681805.2021.1881612.
[11]
Bratt O, Auvinen A, Arnsrud Godtman R, et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps[J]. BMJ Oncol, 2023, 2(1): e000039. DOI: 10.1136/bmjonc-2023-000039.
[12]
林晋华, 谢晓华, 谢晓燕. 经直肠超声在前列腺癌诊断中的应用与新进展[J]. 中国医师杂志, 2023, 25(8): 1121-1124. DOI: 10.3760/cma.j.cn431274-20230628-00910.
[13]
李渝, 罗季平, 但思宇, 等. 经直肠常规超声联合超声造影在前列腺良恶性病灶鉴别诊断中的应用[J]. 中国超声医学杂志, 2023, 39(3): 287-291. DOI: 10.3969/j.issn.1002-0101.2023.03.014.
[14]
Matsugasumi T, Iwata T, Yamada Y, et al. Intraoperative ultrasound monitoring with superb microvascular imaging in focal cryotherapy for prostate cancer[J]. J Med Ultrason (2001), 2022, 49(3): 497-498. DOI: 10.1007/s10396-022-01206-6.
[15]
洪睿霞, 李芳, 周航, 等. 超微血流成像半定量分级在前列腺癌检出中的应用价值[J]. 临床超声医学杂志, 2021, 23(8): 566-569. DOI: 10.16245/j.cnki.issn1008-6978.2021.08.012.
[16]
Turco S, Frinking P, Wildeboer R, et al. Contrast-enhanced ultrasound quantification: from kinetic modeling to machine learning[J]. Ultrasound Med Biol, 2020, 46(3): 518-543. DOI: 10.1016/j.ultrasmedbio.2019.11.008.
[17]
Zhu Y, Chen Y, Jiang J, et al. Comparison of contrast-enhanced ultrasound targeted biopsy versus standard systematic biopsy for clinically significant prostate cancer detection: results of a prospective cohort study with 1024 patients[J]. World J Urol, 2019, 37(5): 805-811. DOI: 10.1007/s00345-018-2441-1.
[18]
高泳, 陈圆圆, 韦丽艳, 等. 前列腺癌超声造影、活检受侵范围与病理新分级分组的相关性[J]. 中国医学影像学杂志, 2022, 30(3): 272-276. DOI: 10.3969/j.issn.1005-5185.2022.03.017.
[19]
刘金炳, 蔡泳仪. 超声新技术在前列腺癌早期诊疗中的应用进展[J]. 广州医科大学学报, 2024, 52(4): 59-64. DOI: 10.3969/j.issn.2095-9664.2024.01.13.
[20]
Ma Q, Yang DR, Xue BX, et al. Transrectal real-time tissue elastography targeted biopsy coupled with peak strain index improves the detection of clinically important prostate cancer[J]. Oncol Lett, 2017, 14(1): 210-216. DOI: 10.3892/ol.2017.6126.
[21]
Xiang LH, Fang Y, Wan J, et al. Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging[J]. Eur Radiol, 2019, 29(12): 6682-6689. DOI: 10.1007/s00330-019-06274-w.
[22]
Loch T. Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies[J]. World J Urol, 2007, 25(4): 375-380. DOI: 10.1007/s00345-007-0181-8.
[23]
Ghai S, Eure G, Fradet V, et al. Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification[J]. J Urol, 2016, 196(2): 562-569. DOI: 10.1016/j.juro.2015.12.093.
[24]
Chen D, Niu Y, Chen H, et al. Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: a retrospective study[J]. Front Oncol, 2022, 12: 994296. DOI: 10.3389/fonc.2022.994296.
[25]
van der Aa AAMA, Mannaerts CK, Gayet MCW, et al. Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study[J]. BMC Urol, 2019, 19(1): 23. DOI: 10.1186/s12894-019-0455-7.
[26]
Grey ADR, Scott R, Shah B, et al. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study[J]. Lancet Oncol, 2022, 23(3): 428-438. DOI: 10.1016/S1470-2045(22)00016-X.
[27]
梁银莹, 李毅, 孔国权, 等. 基于人工智能经直肠超声诊断前列腺癌研究进展[J]. 中国医学影像技术, 2021, 37(10): 1567-1570. DOI: 10.13929/j.issn.1003-3289.2021.10.031.
[28]
吴春梅, 李思琪, 杨存霞, 等. mpMRI影像组学在前列腺癌诊疗中的研究进展[J]. 磁共振成像, 2023, 14(6): 166-170, 191. DOI: 10.12015/issn.1674-8034.2023.06.030.
[29]
Arif M, Starmans MPA, et al. Classification of clinically significant prostate cancer on multi-parametric MRI: a validation study comparing deep learning and radiomics[J]. Cancers (Basel), 2021, 14(1): 12. DOI: 10.3390/cancers14010012.
[30]
Zhang H, Li X, Zhang Y, et al. Diagnostic nomogram based on intralesional and perilesional radiomics features and clinical factors of clinically significant prostate cancer[J]. J Magn Reson Imaging, 2021, 53(5): 1550-1558. DOI: 10.1002/jmri.27486.
[31]
Morote J, Borque-Fernando A, Triquell M, et al. Multiparametric magnetic resonance imaging grades the aggressiveness of prostate cancer[J]. Cancers (Basel), 2022, 14(7): 1828. DOI: 10.3390/cancers14071828.
[32]
王环震, 席玉. MRI、TRUS联合血清PSA诊断前列腺癌的价值观察[J]. 中国CT和MRI杂志, 2022, 20(11): 132-134. DOI: 10.3969/j.issn.1672-5131.2022.11.048.
[33]
刘和洋, 红华, 刘倩. 前列腺癌新辅助内分泌治疗疗效评估的影像学进展[J]. 生物医学工程与临床, 2024, 28(5): 742-747. DOI: 10.13339/j.cnki.sglc.20240819.013.
[34]
许宁, 柯志滨, 陈佳茵. PSMA PET/CT在局限性或局部进展性前列腺癌诊疗中的应用[J]. 现代泌尿外科杂志, 2024, 29(8): 667-672. DOI: 10.3969/j.issn.1009-8291.2024.08.002.
[35]
Niu S, Ding X, Liu B, et al. Radical prostatectomy without prior biopsy in selected patients evaluated by 18F-labeled prostate-specific membrane antigen-ligand positron emission tomography/computed tomography and multiparameter magnetic resonance imaging: a single-center, prospective, single-arm trial[J]. J Urol, 2024, 212(2): 280-289. DOI: 10.1097/JU.0000000000004025.
[36]
刘文, 王淼, 胡桂兰, 等. 18F-PSMA PET/CT联合双参数磁共振对根治性前列腺切除术后病理升级的预测价值[J]. 中华泌尿外科杂志, 2024, 45(3): 180-186. DOI: 10.3760/cma.j.cn112330-20231104-00125.
[37]
邢念增, 王明帅, 杨飞亚, 等. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报(医学版), 2024, 56(4): 565-566. DOI: 10.19723/j.issn.1671-167X.2024.04.003.
[38]
Meissner VH, Rauscher I, Schwamborn K, et al. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography[J]. Eur Urol, 2022, 82(2): 156-160. DOI: 10.1016/j.eururo.2021.11.019.
[39]
de Oliveira Correia ET, Baydoun A, Li Q, et al. Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care[J]. Abdom Radiol, 2024, 49(10): 3696-3710. DOI: 10.1007/s00261-024-04423-4.
[40]
中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南-2023[M]. 北京: 人民卫生出版社, 2023.
[41]
吴炯, 胡嘉华, 施美芳, 等. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195. DOI: 10.3969/j.issn.1673-8640.2023.02.018.
[42]
Thomas J, Atluri S, Zucker I, et al. A multi-institutional study of 1, 111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy[J]. Urol Oncol, 2023, 41(10): 430.e9-430430.e16. DOI: 10.1016/j.urolonc.2023.07.001.
[43]
Voigt JD, Dong Y, Linder V, et al. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system[J]. Rev Urol, 2017, 19(1): 1-10. DOI: 10.3909/riu0753.
[44]
Szeliski K, Adamowicz J, Gastecka A, et al. Modern urology perspectives on prostate cancer biomarkers[J]. Cent European J Urol, 2018, 71(4): 420-426. DOI: 10.5173/ceju.2018.1762.
[45]
Snipaitiene K, Bakavicius A, Lazutka JR, et al. Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: a pilot study[J]. Prostate, 2022, 82(4): 475-482. DOI: 10.1002/pros.24293.
[46]
Jiang P, Bai Y, Yan L, et al. Nanoarchitectonics-assisted simultaneous fluorescence detection of urinary dual miRNAs for noninvasive diagnosis of prostate cancer[J]. Anal Chem, 2023, 95(19): 7676-7684. DOI: 10.1021/acs.analchem.3c00701.
[47]
Delkov D, Yoanıdu L, Tomov D, et al. Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study[J]. Turk J Med Sci, 2022, 52(3): 699-706. DOI: 10.55730/1300-0144.5363.
[48]
Kazemifard N, Sadeghi A, Varaminian B, et al. Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients[J]. Gastroenterology and Hepatology from Bed to Bench, 2019, 12(suppl1): S14-S21.
[49]
Yan W, Xu T, Zhu H, et al. Clinical applications of cerebrospinal fluid circulating tumor DNA as a liquid biopsy for central nervous system tumors[J]. Onco Targets Ther, 2020, 13: 719-731. DOI: 10.2147/OTT.S229562.
[50]
Hahn AW, Stenehjem D, Nussenzveig R, et al. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time[J]. Cancer Treat Res Commun, 2019, 19: 100120. DOI: 10.1016/j.ctarc.2019.100120.
[51]
Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function[J]. J Cell Biol, 2021, 220(2): e202009045. DOI: 10.1083/jcb.202009045.
[52]
Pudova E, Kobelyatskaya A, Emelyanova M, et al. Non-coding RNAs and the development of chemoresistance to docetaxel in prostate cancer: regulatory interactions and approaches based on machine learning methods[J]. Life (Basel), 2023, 13(12): 2304. DOI: 10.3390/life13122304.
[53]
Tan X, Chen WB, Lv DJ, et al. LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer[J]. Cell Death Dis, 2021, 12(2): 138. DOI: 10.1038/s41419-021-03413-4.
[54]
Fang Z, Xu C, Li Y, et al. A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression [J].Cancer Lett, 2016, 374(1):62-74.
[55]
Cui Z, Gao H, Yan N, et al. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis[J]. Aging (Albany NY), 2021, 13(8): 12113-12128. DOI: 10.18632/aging.202919.
[56]
郑江婷, 寸淑娥, 王玉明. 长链非编码RNA在前列腺癌中的研究进展[J]. 现代医药卫生, 2023, 39(11): 1910-1916. DOI: 10.3969/j.issn.1009-5519.2023.11.023.
[57]
冯天玺, 朱赫, 杨晓剑. 前列腺癌相关基因的研究进展[J]. 检验医学与临床, 2023, 20(21): 3214-3220. DOI: 10.3969/j.issn.1672-9455.2023.21.026.
[58]
刘雅惠, 高露, 王亚菁, 等. c-Myc调控肿瘤代谢作用机制的研究进展[J]. 中国药科大学学报, 2021, 52(3): 379-386. DOI: 10.11665/j.issn.1000-5048.20210316.
[59]
Tang DE, Dai Y, He JX, et al. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer[J]. J Pathol, 2020, 252(2): 101-113. DOI: 10.1002/path.5495.
[60]
De Laere B, Oeyen S, Mayrhofer M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2019, 25(6): 1766-1773. DOI: 10.1158/1078-0432.CCR-18-1943.
[61]
王浩, 彭丽娟, 夏中友, 等. 高分组前列腺癌组织中PCDH9表达缺失且与p53、Rb、STAT3的表达相关[J]. 现代泌尿外科杂志, 2024, 29(3): 273-277, 291. DOI: 10.3969/j.issn.1009-8291.2024.03.014.
[62]
Caceres A, Jene A, Esko T, et al. Extreme downregulation of chromosome Y and Alzheimer's disease in men[J]. Neurobiol Aging, 2020, 90: 150.e1-150150.e4. DOI: 10.1016/j.neurobiolaging.2020.02.003.
[63]
Gupta H, Inoue H, Nakai Y, et al. Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer[J]. Cancer Prev Res (Phila), 2023, 16(8): 449-460. DOI: 10.1158/1940-6207.CAPR-22-0485.
[64]
付卫华, 贾维胜, 何凡, 等. 尿沉渣及尿外泌体中PCA3 mRNA评分对前列腺特异抗原灰区患者前列腺癌的诊断价值研究[J]. 局解手术学杂志, 2020, 29(9): 734-738. DOI: 10.11659/jjssx.05E020047.
[65]
陈平舟, 许清江, 林煌, 等. 基于生物信息数据库分析前列腺癌组织特异性lncRNA表达及临床意义[J]. 现代泌尿外科杂志, 2024, 29(3): 232-237, 267. DOI: 10.3969/j.issn.1009-8291.2024.03.007.
[66]
Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy[J]. J Urol, 2008, 179(4): 1354-1360;discussion 1360-1361. DOI: 10.1016/j.juro.2007.11.061.
[67]
Gnanapragasam VJ, Bratt O, Muir K, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study[J]. BMC Med, 2018, 16(1): 31. DOI: 10.1186/s12916-018-1019-5.
[68]
Olah C, Mairinger F, Wessolly M, et al. Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers[J]. Prostate Cancer Prostatic Dis, 2024, 28(3): 773-781. DOI: 10.1038/s41391-024-00918-9.
[69]
邢朋毅, 宋涛, 王铁功, 等. 基于双参数磁共振成像影像组学机器学习的前列腺癌风险分层[J]. 第二军医大学学报, 2021, 42(3): 233-242. DOI: 10.16781/j.0258-879x.2021.03.0233.
[70]
Gong L, Xu M, Fang M, et al. Noninvasive prediction of high-grade prostate cancer via biparametric MRI radiomics[J]. J Magn Reson Imaging, 2020, 52(4): 1102-1109. DOI: 10.1002/jmri.27132.
[71]
赵子涵, 朱文洁, 王鑫, 等. 上尿路尿路上皮癌患者根治术后预后危险因素分析及风险分层模型构建[J]. 临床泌尿外科杂志, 2021, 36(9): 693-698. DOI: 10.13201/j.issn.1001-1420.2021.09.004.
[72]
陈鑫阳, 陈治钦, 谢赣生, 等. 影像组学在预测根治性治疗后前列腺癌生化复发的研究进展[J]. 临床泌尿外科杂志, 2024, 39(7): 636-641. DOI: 0.13201/j.issn.1001-1420.2024.07.015.
[73]
余丽娜, 罗翠, 刘双苔, 等. 前列腺癌筛查健康信念量表的编制与信效度检验[J]. 医学新知, 2025, 35(1): 65-72. DOI: 10.12173/j.issn.1004-5511.202406044.
[1] 薛兆强, 袁寅. 双镜联合保功能胃癌根治术治疗早期近端胃癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 628-632.
[2] 程必盛, 吴芃. 2025EAU年会要点：微创、远程与精准泌尿外科的发展趋势[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 693-699.
[3] 李瑞芳, 王明帅, 邢念增. 循环肿瘤细胞在膀胱癌诊断和预后中的应用进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 705-713.
[4] 田超, 黄若曦, 蒋茂林, 谢崇伟, 刁鹏飞, 钟苏权, 陈东, 王航涛, 陈桂柳, 陈虞娟, 李国良. 不同亚型前列腺癌新辅助化疗后盆腔淋巴结转移的风险因素及时间分布[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 727-735.
[5] 孟维妮, 管旌旌, 刘敏, 王晓雪, 王海凤. 机器人辅助腹腔镜前列腺根治性切除术后合并多种并发症的护理体会[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(06): 765-771.
[6] 陈思鹭, 杨兴, 李学松, 谌诚. 靶向PSMA的荧光探针在前列腺癌显像中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 547-551.
[7] 潘麒文, 何立儒. 前列腺癌放射治疗前沿进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 552-557.
[8] 杨硕, 郭佳. 液体活检在前列腺癌进展监测中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 558-564.
[9] 陈育纯, 王倩倩, 彭天明, 李勇, 田凯文, 刘志烨, 吴坤林, 蒲小勇, 刘久敏. 基于GEO数据库探究前列腺癌淋巴结转移和内脏转移中基因差异及预后[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 579-585.
[10] 余琪伟, 王省博, 姚林亚, 张曦, 吴余凡, 曾学明, 曾庆琪. 经皮胫神经刺激联合索利那新治疗前列腺癌根治术后膀胱功能障碍的疗效观察[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 586-592.
[11] 李玉志, 叶春伟, 杨斌, 杨德林. 机器人辅助下前列腺癌根治术后尿控影响因素的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 658-662.
[12] 唐雪飞, 蒋润民, 倪云峰, 雷杰, 王文辰, 赵雅波, 马首政, 姜涛. 小细胞肺癌和大细胞神经内分泌癌微生物群特征[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(05): 721-726.
[13] 刘丽辉, 白玉新, 张进, 冯巍, 黄琰琰, 邹梦斯, 刘彩红. 血清生物标志物联合检测对支气管哮喘患儿生物靶向治疗效果的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(05): 796-801.
[14] 方兴保, 庞国莲, 李月宏, 蔡艳. 基于多组学分析MCAM在肝癌中表达及其与生存预后和免疫细胞浸润的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 716-724.
[15] 侯雨函, 姜福金, 王苏贵. 膀胱癌免疫治疗的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(06): 471-475.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？